Table 1.
Characteristics of participants enrolled in the AASK trial (N = 1,094), mean (SD) or %
| Blood Pressure Goal |
Initial Medication |
|||||
|---|---|---|---|---|---|---|
| Characteristic | Overall, N = 1,094 | Intensive Goal, N = 540 | Standard Goal, N = 554 | Ramipril, N = 436 | Metoprolol, N = 441 | Amlodipine, N = 217 |
| Age, yr | 54.5 (10.7) | 54.4 (10.9) | 54.5 (10.4) | 54.2 (10.9) | 54.8 (10.4) | 54.3 (10.7) |
| Female, % | 38.8 | 38.1 | 39.5 | 38.8 | 38.5 | 39.6 |
| Mean SBP, mm Hg | 150.3 (23.9) | 151.6 (25.0) | 149.0 (22.6) | 151.0 (23.3) | 149.8 (23.7) | 150.0 (25.3) |
| Mean DBP, mm Hg | 95.5 (14.2) | 96.3 (14.7) | 94.8 (13.7) | 96.0 (14.5) | 95.0 (14.0) | 95.7 (14.1) |
| Mean heart rate, mm Hg | 72.0 (12.6) | 72.3 (12.4) | 71.8 (12.8) | 72.3 (11.7) | 71.6 (12.8) | 72.3 (13.8) |
| Body mass index, kg/m2 | 30.6 (6.6) | 30.5 (6.7) | 30.6 (6.5) | 30.6 (6.3) | 30.9 (6.9) | 29.8 (6.3) |
| Serum creatinine, mg/dL | 2.0 (0.7) | 2.0 (0.7) | 2.0 (0.7) | 2.0 (0.7) | 2.0 (0.7) | 2.1 (0.8) |
| Serum glucose, mg/dL | 95.0 (18.5) | 95.5 (19.4) | 94.5 (17.5) | 94.5 (17.7) | 96.0 (18.8) | 93.8 (19.2) |
| Total number of visits, N | 52,877 | 26,810 | 26,067 | 21,395 | 21,396 | 10,086 |
| Pre-randomization N of visits per participant, mean (SD) | 3.6 (1.2) | 3.6 (1.2) | 3.6 (1.3) | 3.6 (1.1) | 3.7 (1.2) | 3.6 (1.5) |
| Post-randomization N of visits per participant, mean (SD) | 44.9 (21.2) | 46.3 (21.4) | 43.5 (21.0) | 45.6 (22.8) | 44.8 (20.1) | 43.5 (20.2) |
Note: These characteristics values represent the earliest visit of participants enrolled in the study (almost always the screening visit). Participants had on average 3.6 visits (screening visits or blood pressure medication titration visits) during the period preceding randomization.